Medtronic

Medtronic: A Timeline of Events1949:* Earl Bakken and Palmer Hermundslie found Medtronic in a Minneapolis garage as a medical equipment repair service, initially focused on electrocardiogram machines and lab instruments.Early 1950s:* Medtronic operates on tight margins, with one month reportedly earning only $8 in revenue.* The "garage gang" perseveres, driven by a passion to help others.* Bakken improvises and crafts over 100 custom devices for medical researchers, often using surplus parts. These include primitive defibrillators and cardiac monitors.1957:* A power blackout in Minneapolis on Halloween night causes pacemakers in a hospital to fail, tragically resulting in the death of one infant recovering from heart surgery.* The following day, Dr. C. Walton Lillehei challenges Earl Bakken to create a battery-powered pacemaker.* Bakken, inspired by a Popular Electronics article, develops a small, battery-operated, wearable pacemaker within a few weeks.* Dr. Lillehei immediately uses Bakken's prototype on a child, successfully keeping their heart in rhythm. This marks the beginning of mobile cardiac pacing.1958:* News of the wearable pacemaker spreads rapidly, and hospitals begin placing orders.* Medtronic, in partnership with Dr. William Chardack and engineer Wilson Greatbatch, introduces the first implantable pacemaker.1960:* Medtronic secures exclusive rights to manufacture the Chardack-Greatbatch implantable pacemaker, shifting its focus to developing and selling its own life-sustaining devices.* Orders for implantable pacemakers pour in.* Medtronic moves out of the garage into its first proper headquarters.* A small sales force is hired to cover the United States and Canada.* Faced with financial strain due to heavy R&D spending, Earl Bakken drafts the Medtronic Mission Statement, with the core tenet: "To contribute to human welfare by application of biomedical engineering to alleviate pain, restore health, and extend life."* Bakken starts the annual Medtronic holiday party featuring patient testimonials.Early 1960s:* Medtronic expands its product line to include heart monitors, defibrillators, and other cardiac support devices.* Annual sales climb to over $500,000 by 1962.Late 1960s:* Medtronic becomes the leader in cardiac rhythm management, refining pacemakers with improved battery life and reliability.* The company begins exploring applications of electrical stimulation for other medical problems, prototyping early neuromodulators for pain management.1970s:* Medtronic experiences significant expansion, commanding around 35% of the global pacemaker market by the mid-70s.* Annual sales surpass $100 million in 1975 and $200 million by 1979.* In 1977, Medtronic is listed on the New York Stock Exchange.* The company diversifies into diabetes care, neurosurgery, and orthopaedic/spinal therapy.* Medtronic introduces the Medtronic-Hall mechanical heart valve (1977) and steroid-eluting cardiac leads.* Acquisitions include Medical Data Systems (nuclear imaging equipment, 1978) and Energy Technology (lithium batteries, later Promeon).* Earl Bakken steps down as president in 1974, becoming chairman of the board. He is succeeded by Thomas Holloran and then Dale Olseth as CEO.* The Medtronic Foundation is established in 1979.* The Bakken Society is founded in 1979 to recognise top scientists and engineers.1980s:* Medtronic continues to refine cardiac rhythm management with programmable pacemakers (Spectrax, 1981) and rate-responsive pacemakers (Activitrax, 1985).* Acquisitions include Biotech (Italy) and Vitatron (Netherlands) in 1986, strengthening its position in rate-responsive pacing and Europe.* Regional headquarters are established in Europe and Latin America, and manufacturing plants open internationally.* Medtronic develops an implantable neurostimulator for chronic pain and collaborates on the world's first deep brain stimulation (DBS) system for movement disorders (1987).* By the end of the decade, Medtronic has six primary business areas beyond pacemakers.1985:* Winston "Win" Wallin is hired as CEO.1989:* Earl Bakken retires as chairman of the board.Early 1990s:* Under Win Wallin's leadership (1985-1991), Medtronic's sales more than triple, exceeding $1 billion by 1991.* Medtronic introduces its first implantable cardioverter-defibrillator (ICD) in 1993.1991:* William W. "Bill" George succeeds Win Wallin as CEO.1990s:* Under Bill George's leadership (1991-2001), Medtronic aggressively expands into new therapies through R&D and acquisitions.* The company cultivates a highly engaged workforce and becomes Minnesota's most valuable company.* Medtronic launches the Activa DBS device.* The Spinal Modulation business is boosted by the acquisition of Sofamor Danek.Early 2000s:* Arthur "Art" Collins takes over from Bill George as CEO in 2001.* Medtronic acquires MiniMed in 2001, entering the diabetes management field with insulin pumps.* Revenues surge past $10 billion under Collins (2001-2007), fueled by major acquisitions like Sofamor Danek and MiniMed.* Medtronic launches the industry’s first remote device monitoring system in 2002.2007:* Bill Hawkins assumes the CEO role (2007-2011).* Medtronic faces a high-profile recall of its Sprint Fidelis heart device leads.* Hawkins advances innovations like the first transcatheter heart valves.2011:* Omar Ishrak is appointed CEO – the first person of colour and first external hire to lead the company.2010s:* Under Omar Ishrak (2011-2020), Medtronic focuses on global expansion and efficiency.* In 2015, Medtronic acquires Covidien for $42.9 billion, nearly doubling its size and broadening its offerings. The legal headquarters move to Ireland in a tax inversion.* Medtronic introduces the Micra leadless pacemaker (2016) and the MiniMed 670G automated insulin dosing system (2016).* The Infuse bone graft controversy leads to investigations and settlements.* Acquisition of Mazor Robotics (spine surgery robotics, 2018).* Medtronic becomes the market leader in TAVR (transcatheter aortic valve replacement) by 2019.2020:* Geoff Martha becomes CEO after Ishrak's retirement.* Medtronic recalls around 322,000 MiniMed insulin pumps due to a safety issue.* During the COVID-19 pandemic, Medtronic open-sources a ventilator design and significantly increases its own ventilator production.* Launch of the MiniMed 780G system in Europe.Early 2020s:* Medtronic's Hugo™ Robotic Assisted Surgery (RAS) system performs its first patient procedures in Europe (2021).* Acquisition of Intersect ENT (sinus implants, 2022).* Medtronic faces global supply chain disruptions and inflationary pressures.* The company undertakes cost-cutting and efficiency programs.* Spinoff of the Renal Care Solutions business into Mozarc Medical (2023) and plans to separate the Patient Monitoring and Respiratory Interventions businesses.* Medtronic reports its products touch over 74 million patients annually by 2023.Future Outlook:* Focus on integrating artificial intelligence and data science into products and services.* Continued expansion of access to therapies in developing markets through frugal innovation.* More collaboration and open innovation initiatives.* Strategic investments in high-growth areas like cardiac ablation, structural heart, neuromodulation, and surgical robotics.* Maintaining a culture of innovation and agility while upholding the core mission. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.uhaid.org